We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

34 hedge funds and large institutions have $378M invested in ProQR Therapeutics in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more capital invested

Capital invested by funds: $80.8M → $378M (+$297M)

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

36% more funds holding

Funds holding: 25 → 34 (+9)

16.81% more ownership

Funds ownership: 34.68% → 51.49% (+17%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
34
Holders Change
+9
Holders Change %
+36%
% of All Funds
0.78%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
8
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$39.7M
2
RG
Redmile Group
California
+$15.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$13.8M
4
PA
Perceptive Advisors
New York
+$8.09M
5
O
OrbiMed
New York
+$7.81M

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$2.28M
2
AG
Artal Group
Luxembourg
-$2.13M
3
JGC
J. Goldman & Co
New York
-$1.62M
4
Millennium Management
Millennium Management
New York
-$1.43M
5
SFM
Sphera Funds Management
Israel
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$72.4M +$39.7M +3,739,406 New
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$67M +$13.8M +1,299,414 +60%
Jennison Associates
3
Jennison Associates
New York
$58M +$180K +16,889 +0.6%
O
4
OrbiMed
New York
$39.4M +$7.81M +734,920 +56%
RG
5
Redmile Group
California
$28.1M +$15.4M +1,450,925 New
AG
6
Artal Group
Luxembourg
$25.2M -$2.13M -200,000 -13%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$16.4M +$6.47M +608,397 +256%
PA
8
Perceptive Advisors
New York
$14.7M +$8.09M +761,000 New
ClearBridge Investments
9
ClearBridge Investments
New York
$9.54M +$2.02K +190 +0%
Morgan Stanley
10
Morgan Stanley
New York
$7.86M +$1.23M +115,709 +40%
SFM
11
Sphera Funds Management
Israel
$7.72M -$1.01M -95,000 -19%
Federated Hermes
12
Federated Hermes
Pennsylvania
$5.06M +$2.78M +261,400 New
DCM
13
DAFNA Capital Management
California
$5.04M +$946K +88,985 +52%
AGA
14
Altrinsic Global Advisors
Connecticut
$3.7M – – –
OPPM
15
Opus Point Partners Management
New York
$2.68M -$164K -15,385 -10%
MIM
16
Monashee Investment Management
Massachusetts
$2.13M – – –
OAM
17
Oxford Asset Management
United Kingdom
$2.08M +$1.14M +106,959 New
PC
18
Polar Capital
United Kingdom
$1.94M +$1.06M +100,000 New
CS
19
Credit Suisse
Switzerland
$1.43M -$266K -25,000 -25%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$1.37M +$751K +70,686 New
FSA
21
Franklin Street Advisors
North Carolina
$1.16M -$319K -30,000 -33%
PVI
22
Pura Vida Investments
New York
$1.1M -$2.28M -214,356 -79%
NC
23
Nexthera Capital
New York
$1.02M +$562K +52,875 New
EIM
24
Essex Investment Management
Massachusetts
$586K -$558K -52,477 -63%
AAP
25
Ardsley Advisory Partners
Connecticut
$484K -$266K -25,000 -50%
1
2

PRQR Hedge Fund Activity: Q3 2018 in Review

34 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2018, worth a combined $378M — up 367% from $80.8M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PRQR positions and 4 closed out — a net gain of 9 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $39.7M. The largest seller was Pura Vida Investments, cutting an estimated $2.28M.

  • 34 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2018, up from 25 in Q2 2018.
  • Funds reported $378M of ProQR Therapeutics stock for Q3 2018, up 367% quarter-over-quarter.
  • 13 funds opened new ProQR Therapeutics positions in Q3 2018 and 4 closed out, a net change of +9 holders.
  • The largest ProQR Therapeutics buyer in Q3 2018 was RTW Investments, an estimated $39.7M added.
  • The largest ProQR Therapeutics seller in Q3 2018 was Pura Vida Investments, an estimated $2.28M sold.

Based on aggregated 13F filings for Q3 2018.